Recent legislation and pressures to adopt value-based pricing are reshaping the pharmaceutical marketplace, bringing fundamental change.
Pharma and biotech companies need to demonstrate that their brand adds value to patients. I2E can provide an efficient starting point, performing evidence-based systematic reviews over very large sets of scientific literature.
- I2E enables researchers to answer questions such as:
- What is the economic burden of disease X?
- Does Y new intervention merit funding?
- What are the economic implications of its use?
In the current competitive marketplace for healthcare, pharmaceutical and medical technology companies must be able to demonstrate clinical and economic evidence of benefit to providers, healthcare decision-makers and payers. Now more than ever, pricing pressure and regulatory restrictions are generating increased demand for this kind of outcomes evidence.
HEOR aims to assess the direct and indirect health care costs associated with a disease or a therapeutic area, and associated interventions in real-world clinical practice. These costs include:
- Direct economic loss
- Economic loss through hospitalization
- Indirect costs from loss of wider societal productivity
The availability of increasing amounts of data on patients, prescriptions, markets, and scientific literature – combined with the wider use of comparative effectiveness – make traditional keyword based search techniques ineffectual. I2E can provide the starting point for efficiently performing evidence based systematic reviews over very large sets of scientific literature, enabling researchers to answer questions such as:
- What is the economic burden of disease within the healthcare system?
- Does XYZ new intervention merit funding? What are the economic implications of its use?
- How do the incremental costs compare with the anticipated benefits for specific patient groups?
- How does treatment XYZ affect quality of life? Activities of daily living? Health status indicators? Patient satisfaction?